MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Total Shareholders Equity 2011-2026 | NDRA
Annual Total Shareholders Equity ENDRA Life Sciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.56 M | 5.66 M | 7.2 M | 10.8 M | 7.17 M | 4.76 M | 6.25 M | 5.28 M | -894 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.8 M | -894 K | 5.42 M |
Quarterly Total Shareholders Equity ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 171 K | 1.47 M | 1.75 M | 2.56 M | 6.6 M | 8.99 M | 3.7 M | 5.66 M | 5.2 M | 6.93 M | 4.5 M | 7.2 M | 10.2 M | 13.3 M | 9.07 M | 10.8 M | 13.2 M | 15 M | 17.9 M | 7.17 M | 7.17 M | 7.17 M | 7.17 M | 4.76 M | 4.76 M | 4.76 M | 4.76 M | 6.25 M | 6.25 M | 6.25 M | 6.25 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | -894 K | -894 K | -894 K | -894 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.9 M | -894 K | 6.01 M |
Total Shareholders Equity of other stocks in the Diagnostics research industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
27.5 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
184 M | $ 9.2 | 2.17 % | $ 613 M |  USA |
|
Biodesix
BDSX
|
20.9 M | $ 15.36 | 4.56 % | $ 1.99 B | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.14 | 0.47 % | $ 4.92 M | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 16.25 | -0.49 % | $ 491 M | USA |
 |
Guardant Health
GH
|
-99.3 M | $ 83.44 | -1.79 % | $ 10.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 102.22 | 1.86 % | $ 8.43 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.61 B | $ 572.04 | -1.12 % | $ 46 B | USA |
|
Akumin
AKU
|
-48.2 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 74.38 | -1.79 % | $ 5.02 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M |  Israel |
 |
Medpace Holdings
MEDP
|
459 M | $ 463.54 | 1.45 % | $ 13.4 B | USA |
 |
Myriad Genetics
MYGN
|
368 M | $ 4.67 | 0.11 % | $ 432 M | USA |
 |
National Research Corporation
NRC
|
14 M | $ 17.35 | -0.91 % | $ 388 M | USA |
 |
Pacific Biosciences of California
PACB
|
5.35 M | $ 1.39 | -0.36 % | $ 417 M | USA |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
86 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Precipio
PRPO
|
14.4 M | $ 27.01 | 0.3 % | $ 35.1 M | USA |
 |
Personalis
PSNL
|
203 M | $ 7.71 | 1.31 % | $ 457 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M |  China |
 |
RadNet
RDNT
|
1.09 B | $ 59.66 | -3.37 % | $ 4.49 B | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.69 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
3.16 B | $ 159.73 | 1.09 % | $ 7.92 B | USA |
 |
IQVIA Holdings
IQV
|
6.5 B | $ 165.68 | -0.77 % | $ 28.5 B | USA |
 |
Sotera Health Company
SHC
|
606 M | $ 13.83 | -0.36 % | $ 3.93 B | USA |
 |
Soleno Therapeutics
SLNO
|
450 M | $ 31.01 | -2.24 % | $ 1.58 B | USA |
 |
Neuronetics
STIM
|
22.4 M | $ 1.45 | -9.69 % | $ 95.6 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
44.4 M | $ 1.23 | -15.75 % | $ 6.7 M | USA |
 |
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 263.12 | 1.94 % | $ 26 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
-2.22 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
2.37 B | $ 125.57 | 1.44 % | $ 20 B | USA |
 |
QIAGEN N.V.
QGEN
|
3.57 B | - | - | $ 10.6 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
473 M | $ 46.42 | 4.31 % | $ 2.78 B | USA |
 |
Celcuity
CELC
|
116 M | $ 101.62 | -4.81 % | $ 4.01 B | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.62 B | $ 267.18 | 1.04 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
NeoGenomics
NEO
|
837 M | $ 7.91 | -2.41 % | $ 1.01 B | USA |
 |
Natera
NTRA
|
706 M | $ 194.73 | -2.68 % | $ 19.2 B | USA |
 |
Senseonics Holdings
SENS
|
61 M | $ 6.62 | - | $ 276 M | USA |